A detailed history of Royce & Associates LP transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Royce & Associates LP holds 13,334 shares of VKTX stock, worth $701,235. This represents 0.01% of its overall portfolio holdings.

Number of Shares
13,334
Holding current value
$701,235
% of portfolio
0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$49.84 - $70.47 $664,566 - $939,646
13,334 New
13,334 $844,000
Q1 2024

May 13, 2024

SELL
$17.4 - $94.5 $366,896 - $1.99 Million
-21,086 Reduced 75.21%
6,951 $569,000
Q4 2023

Feb 12, 2024

BUY
$9.24 - $19.64 $259,061 - $550,646
28,037 New
28,037 $521,000
Q1 2019

May 09, 2019

SELL
$7.58 - $9.94 $1.02 Million - $1.34 Million
-135,000 Closed
0 $0
Q4 2018

Feb 11, 2019

BUY
$7.16 - $16.21 $966,600 - $2.19 Million
135,000 New
135,000 $1.03 Million

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $4.03B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Royce & Associates LP Portfolio

Follow Royce & Associates LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royce & Associates LP, based on Form 13F filings with the SEC.

News

Stay updated on Royce & Associates LP with notifications on news.